Maxigen Biotech Inc.

Informe acción TWSE:1783

Capitalización de mercado: NT$3.7b

Salud financiera de hoja de balance de Maxigen Biotech

Salud financiera controles de criterios 6/6

Maxigen Biotech has a total shareholder equity of NT$1.3B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$1.6B and NT$236.5M respectively. Maxigen Biotech's EBIT is NT$124.9M making its interest coverage ratio -5.1. It has cash and short-term investments of NT$520.8M.

Información clave

0%

Ratio deuda-patrimonio

NT$0

Deuda

Ratio de cobertura de intereses-5.1x
EfectivoNT$520.79m
PatrimonioNT$1.33b
Total pasivoNT$236.54m
Activos totalesNT$1.57b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Apr 22
Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Apr 01
We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 16
Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Feb 23
The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Feb 02
Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Jan 10
Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Dec 14
Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Nov 22
If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Análisis de la situación financiera

Pasivos a corto plazo: 1783's short term assets (NT$728.6M) exceed its short term liabilities (NT$235.6M).

Pasivo a largo plazo: 1783's short term assets (NT$728.6M) exceed its long term liabilities (NT$942.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 1783 is debt free.

Reducción de la deuda: 1783 has no debt compared to 5 years ago when its debt to equity ratio was 26%.

Cobertura de la deuda: 1783 has no debt, therefore it does not need to be covered by operating cash flow.

Cobertura de intereses: 1783 has no debt, therefore coverage of interest payments is not a concern.

Hoja de balance

Descubre empresas con salud financiera

7D

1Y

7D

1Y

7D

1Y